CN106478692A - Copper-nitrate complex and its synthetic method and application with 1 (2 pyridine) 9 benzyl β carboline as part - Google Patents
Copper-nitrate complex and its synthetic method and application with 1 (2 pyridine) 9 benzyl β carboline as part Download PDFInfo
- Publication number
- CN106478692A CN106478692A CN201610855415.6A CN201610855415A CN106478692A CN 106478692 A CN106478692 A CN 106478692A CN 201610855415 A CN201610855415 A CN 201610855415A CN 106478692 A CN106478692 A CN 106478692A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- synthetic method
- polar solvent
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000010189 synthetic method Methods 0.000 title claims abstract description 21
- XTVVROIMIGLXTD-UHFFFAOYSA-N copper(II) nitrate Chemical compound [Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O XTVVROIMIGLXTD-UHFFFAOYSA-N 0.000 title claims abstract description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title abstract description 15
- KHYHEDVODKJBGZ-UHFFFAOYSA-N 9-benzylpyrido[3,4-b]indole Chemical compound C12=CC=CC=C2C2=CC=NC=C2N1CC1=CC=CC=C1 KHYHEDVODKJBGZ-UHFFFAOYSA-N 0.000 title abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims abstract description 54
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000002798 polar solvent Substances 0.000 claims abstract description 28
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 7
- 239000012467 final product Substances 0.000 claims abstract description 5
- 238000010668 complexation reaction Methods 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 37
- 239000000047 product Substances 0.000 claims description 27
- 239000010949 copper Substances 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 24
- 239000013078 crystal Substances 0.000 claims description 21
- 239000003960 organic solvent Substances 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 14
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 claims description 12
- 229940125782 compound 2 Drugs 0.000 claims description 11
- 239000007800 oxidant agent Substances 0.000 claims description 11
- 230000001590 oxidative effect Effects 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 9
- 239000000376 reactant Substances 0.000 claims description 8
- 229940125904 compound 1 Drugs 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 claims description 5
- ACKFDYCQCBEDNU-UHFFFAOYSA-J lead(2+);tetraacetate Chemical compound [Pb+2].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ACKFDYCQCBEDNU-UHFFFAOYSA-J 0.000 claims description 5
- MSBWDNNCBOLXGS-UHFFFAOYSA-L manganese(2+);diacetate;hydrate Chemical compound O.[Mn+2].CC([O-])=O.CC([O-])=O MSBWDNNCBOLXGS-UHFFFAOYSA-L 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- AQZMINLSVARCSL-UHFFFAOYSA-N 4-chloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound ClC1=CC(=O)C(C#N)=C(C#N)C1=O AQZMINLSVARCSL-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 2
- 150000007529 inorganic bases Chemical group 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 229910017604 nitric acid Inorganic materials 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 229910052697 platinum Inorganic materials 0.000 abstract description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940034982 antineoplastic agent Drugs 0.000 abstract description 2
- 229910002651 NO3 Inorganic materials 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 238000001819 mass spectrum Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000011259 mixed solution Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000001308 synthesis method Methods 0.000 description 6
- 239000005388 borosilicate glass Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 0 CC=CC=C(*[N+](*1C=C2)[I-])C1C(*1C*3=CC=CCC3)=C2c2c1cccc2 Chemical compound CC=CC=C(*[N+](*1C=C2)[I-])C1C(*1C*3=CC=CCC3)=C2c2c1cccc2 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101000905241 Mus musculus Heart- and neural crest derivatives-expressed protein 1 Proteins 0.000 description 1
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical class ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229930002341 quinoline alkaloid Natural products 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses copper-nitrate complex and its synthetic method and application of the one kind with 1 (2 pyridine) 9 benzyl β carboline as part.Shown in the structural formula of the complex such as following formula (I), its synthetic method is:Compound and copper nitrate as shown in following formula (II) is taken, is dissolved in polar solvent, complexation reaction is carried out, is obtained final product;Wherein, described polar solvent is one or two and one or more the combination in water, acetone, chloroform, dichloromethane and N, the N dimethylformamide in methyl alcohol and ethanol.Complex of the present invention shows the antitumor activity more higher than part and cis-platinum, with preferably potential medical value, is expected to be used for the preparation of various antineoplastics.Formula (I) and structure shown in formula (II) as follows:
Description
Technical field
The present invention relates to pharmaceutical technology field, and in particular to a kind of with 1- (2- pyridine) -9- benzyl-B-carboline as part
Copper-nitrate complex and its synthetic method and application.
Background technology
B-carboline is the alkaloid that a class is distributed widely in nature, and they are primarily present in multiple terrestrial plants and ocean
In biology.Chemically classify in structure, beta-carboline alkaloid belongs to indoles alkaloid, and it is three be made up of trypoline
Member ring systems, its skeleton are planar molecules, and two nitrogen-atoms of wherein 2 and 9 are present with different hybridization states,
9 nitrogen-atoms are sp3Hydridization, is rich pi-electron system, and 2 nitrogen-atoms are sp2Hydridization, is to lack pi-electron system.Two nitrogen-atoms with
The chemical property and biologically active of such compound is closely related.Such compound has extensive biology and pharmacology is lived
Property, including:Sedative, antianxiety, hypnosis, anti-spasm, antitumor, antiviral, desinsection and antibacterial activity etc..Therefore β-click
Quinoline alkaloid is increasingly paid attention to by researcher.
On the other hand, the Pharmaceutical Inorganic Chemistry based on medical active part is studied in recent years with bioinorganic chemistry
Flourish and become hot research field, the first, second and third generation platinum class especially with cis-platinum, carboplatin, oxaliplatin etc. as representative
Cancer therapy drug really indicates the arrival of Metal Drugs research and application New Times as the successful Application of front-line chemotherapeutic agents.
But copper nitrate (II) complex having not yet to see with 1- (2- pyridine) -9- benzyl-B-carboline as part and its synthetic method
Relevant report with application.
Content of the invention
The technical problem to be solved in the present invention is a kind of structure novelty of offer with 1- (2- pyridine) -9- benzyl-B-carboline
Copper nitrate (II) complex for part, and its synthetic method and application,
The present invention relates to compound shown in lower formula (I) or its pharmaceutically acceptable salt:
Shown in above-mentioned formula (I), the synthetic method of compound is:Take compound and copper nitrate (Cu as shown in following formula (II)
(NO3)2·3H2O), it is dissolved in polar solvent, complexation reaction is carried out, that is, obtains target product;Wherein, described polar solvent is
In methyl alcohol and ethanol one or two with water, acetone, chloroform, dichloromethane and the DMF
One or more combination;
Compound shown in the raw material formula (II) being related in above-mentioned synthetic method participates in reaction as part, and its chemical name is
1- (2- pyridine) -9- benzyl-B-carboline, also referred to as L in this application.Compound shown in the formula (II) can designed, designed synthesis
Route is prepared, and is preferably prepared as follows:
With tryptamines and pyridine-2-formaldehyde as raw material, react in the first organic solvent, compound is obtained through dehydrating condensation
1;Then compound 1 is placed in the second organic solvent, add oxidant cyclization dehydrogenation obtain compound 2 (1- (2- pyridine)-
B-carboline);Again compound 2 is placed in the aprotic polar solvent of alkaline matter, adds bromination that substitution reaction is carried out, i.e.,
?;Wherein:
The first described organic solvent is the one kind or two in toluene, methyl alcohol, ethanol, dichloromethane and chloroform
Plant above combination;
The second described organic solvent is the one kind or two in benzene, toluene, paraxylene, glacial acetic acid and dichloromethane
Plant above combination;
Described oxidant is palladium carbon, manganese acetate hydrate (Mn (Ac)3·nH2O), lead tetraacetate (Pb (Ac)4) or 2,3-
Two chloro- 5,6- dicyan 1,4-benzoquinone (DDQ);
Described alkaline matter is inorganic base;
Described aprotic polar solvent be the one kind in N,N-dimethylformamide, dimethyl sulfoxide (DMSO) and acetone or
Two or more combinations.
Shown in above-mentioned preparation formula (II), the synthetic route of compound method is as follows:
Reagent:(a) first organic solvent;(b) oxidant, the second organic solvent;C () alkaline matter, aprotonic polar are molten
Agent.
The more specifically preparation method of compound shown in above-mentioned formula (II), comprises the following steps:
1. with tryptamines and pyridine-2-formaldehyde as raw material, react in the first organic solvent, in course of reaction, discharge reaction life
The water for becoming, question response terminate rear solvent evaporated, obtain compound 1;
2. compound 1 is placed in the second organic solvent, oxidant is added, react under heating condition, question response terminates, mistake
Filter, collects filtrate, is evaporated, obtains compound 2;
3. take alkaline matter to be dissolved in aprotic polar solvent, be subsequently adding compound 2 and cylite is reacted, treat anti-
Should terminate, reactant be put in frozen water, gained mixture of ice and water is extracted, collection organic phase, solvent evaporated, that is, obtain
Compound shown in formula (II) (i.e. compound 3).
Shown in above-mentioned formula (II) the step of compound synthesis method 1. in, the amount of the material of tryptamines and pyridine-2-formaldehyde it
Than being usually 0.8~1.2:1, reaction can be carried out under conditions of being heated or not heated, and can use water knockout drum in course of reaction
The water that reaction is generated is discharged, whether reaction can adopt thin-layer chromatography (TLC) tracing detection completely;Preferably, reaction is adopted
Heating reflux reaction, the time control that now reacts are appropriate in 2~6h.In the step, obtained is the thick product of compound 1
Thing, in order to reduce the impurity in subsequent reactions, improves the yield of postorder reaction, preferably carries out after purification process to residue obtained
Postorder reaction is carried out again.Specific purification process can be recrystallized with little polar solvent to residue obtained, and gained recrystallization is produced
Thing is used further to postorder reaction.Described for recrystallize little polar solvent same as the prior art, can be specifically petroleum ether and/
Or n-hexane etc..
Shown in above-mentioned formula (II) the step of compound synthesis method 2. in, reaction preferably adopt heating reflux reaction, reaction
Whether thin-layer chromatography tracing detection can be adopted completely.In the step, obtained is the crude product of compound 2, in order to reduce
Impurity in subsequent reactions, improves the yield of postorder reaction, preferably carries out carrying out postorder after purification process again to residue obtained
Reaction.Specific purification process can be to residue obtained with methyl alcohol, ethanol and dichloromethane one or two with
On combination solvent recrystallized, or residue obtained upper silica gel column chromatography is purified, in upper silica gel column chromatography, used
Eluant, eluent be that petroleum ether and dichloromethane press 6:1~1:The mixed solvent of 1 volume ratio composition.
Shown in above-mentioned formula (II) the step of compound synthesis method 2. in, according to the difference of oxidant, from different
Two organic solvents, specific as follows:
(1) when oxidant is when being chosen as palladium carbon, the second organic solvent is preferably the one kind in benzene, toluene and paraxylene
Or two or more combinations, when two organic solvents be chosen as more than above two combination when, the proportioning between them is permissible
For any proportioning.Described palladium carbon can be 5%Pd/C or 10%Pd/C, and the addition of the palladium carbon generally presses 10mmol chemical combination
Thing 1 adds 2~4g palladium carbon to calculate.
(2) when oxidant is when being chosen as manganese acetate hydrate or lead tetraacetate, the second organic solvent is preferably glacial acetic acid;
The addition of the manganese acetate hydrate or lead tetraacetate is usually 2~8 times of the amount of 1 material of compound.Choosing when oxidant
When manganese acetate hydrate or lead tetraacetate is selected as, pH >=7 with alkali lye regulation system after terminating preferably is reacted, then which is extracted
Take, organic phase is collected, the residue of solvent evaporated gained goes up silica gel column chromatography purifying again;Wherein, described alkali lye can be ammoniacal liquor,
The aqueous solution of the alkaline matters such as sodium acetate, sodium carbonate, sodium phosphate, sodium acid carbonate or potassium carbonate, the concentration of the alkali lye are preferably 5
~30w/w%;Can be specifically ethyl acetate, dichloromethane, chloroform or ether etc. for extracting the solvent for adjusting system after pH value.
(3) when oxidant is when being chosen as bis- chloro- 5,6- dicyan 1,4-benzoquinone of 2,3-, the second organic solvent is preferably benzene, first
One or more combination of benzene and dichloromethane, when two organic solvents be chosen as more than above two combination when,
Proportioning between them can be any proportioning.The addition of the chloro- 5,6- dicyan 1,4-benzoquinone of the 2,3- bis- is usually compound 1
1~4 times of the amount of material.
Shown in above-mentioned formula (II) the step of compound synthesis method 3. in, the alkaline matter, compound 2 and cylite
The ratio of the amount of material is usually 1~4:1:1~3, alkaline matter therein can be sodium hydride, calcium hydride, hydroxide further
One or more combination in calcium, NaOH, potassium hydroxide, cesium carbonate and potassium carbonate, when the selection of alkaline matter
For, during more than above two combination, the proportioning between them can be any proportioning.In the step, reaction can be 0~80
Carry out under the conditions of DEG C, whether reaction can adopt thin-layer chromatography (TLC) tracing detection completely;Preferably, react 20~50
DEG C, the time control that now reacts is appropriate in 1~6h.The solvent extracted by mixture of ice and water can be specifically acetic acid second
The conventional extraction solvent such as ester, dichloromethane, chloroform, petroleum ether or ether.
In compound synthesis method shown in above-mentioned formula (II), involved various solvents are (as the first organic solvent, second have
Machine solvent and aprotic polar solvent etc.) consumption, with can dissolve participate in each step react raw material be advisable.
What said method was prepared is the crude product of compound shown in formula (II), in order to be improved shown in formula (II) further
The purity of compound, is more beneficial for the carrying out of subsequent reactions, preferably above-mentioned gained crude product is carried out being used after purification process again
In the synthetic method of target product of the present invention.Described purification process is same as the prior art, can be specifically by crude product
Upper silica gel column chromatography purifying, to obtain pure compounds shown in formula (II);In upper silica gel column chromatography, eluant, eluent used is two
Chloromethanes and methyl alcohol press 1000:1~50:The mixed solvent of 1 volume ratio composition.
In the synthetic method of compound shown in formula (I) of the present invention, in the composition of polar solvent, methyl alcohol or ethanol or
Person is that the ratio shared in polar solvent of combination of methyl alcohol and ethanol is preferably 50~98v/v%;When containing in polar solvent
During two or more selection in water, acetone, chloroform, dichloromethane and DMF, do not surpass in their total amount
Go out under 50% precondition, their proportioning can be any proportioning.The consumption of the polar solvent can determine as needed,
Under normal circumstances, the copper nitrate of 1mmol and compound shown in 1mmol formula (II) are dissolved with the polar solvent of 5~80mL.In tool
In the dissolving step of body, typically by additive polarity solvent again after copper nitrate and the mixing of compound shown in formula (II);Also can be by copper nitrate
Dissolved with polar solvent with compound shown in formula (II) respectively, remix and react together.
In the synthetic method of compound shown in formula (I) of the present invention, the copper nitrate and compound shown in formula (II)
The ratio of the amount of material can be 1~6:1.
Compound shown in formula (I) of the present invention, can be using normal pressure solwution method or high pressure solvent warm specifically in synthesis
Method is synthesized.
When using normal pressure solwution method, its synthetic method includes:Compound shown in formula (II) and copper nitrate is taken, is dissolved in polarity
In solvent, gained mixed liquor is reacted under the conditions of being heated or not heated, and reactant removes partial solvent, is stood, and is separated out, is isolated
Crystal, obtains final product target product.
In above-mentioned normal pressure solwution method, reaction can be carried out in 20 DEG C to polar solvent of reflow temperature range, preferably adopted
With back flow reaction, further preferably reaction is carried out in 50 DEG C to polar solvent of reflow temperature range, more preferably 60
React under the conditions of DEG C.Whether reaction can adopt thin-layer chromatography tracing detection completely.In this method, product is typically in the form of crystal
A large amount of generations, if in previous step, the addition of polar solvent is larger (being such as close to the upper limit of proportioning) or solvent is to the molten of product
Preferably, then after reacting, solution may be in clear state to solution property, this is because the product precipitation for being formed is dissolved institute by polar solvent
Cause, now gained reactant liquor can be concentrated or vacuum distillation is to remove partial solvent, typically concentrate and remove polar solvent addition
The 50~90% of amount.Isolated solid can be washed with ether, acetone, ethanol, methyl alcohol or dichloromethane further, it
It is dried again afterwards.
When the hot method of high pressure solvent, its synthetic method includes:Compound shown in formula (II) and copper nitrate is taken, is dissolved in polarity molten
In agent, gained mixed liquor is placed in container, is evacuated to vacuum after liquid nitrogen frozen, sealing by fusing, then anti-under the conditions of 30~140 DEG C
Should, obtain target product.
In the hot method of above-mentioned high pressure solvent, described container is usually heavy wall borosilicate glass tube, reacts generally at 30~140 DEG C
Under the conditions of carry out, under this temperature conditions, the time of reaction is preferably controlled in 2~24h, extends to also dependent on actual conditions
More than 24h.Further preferably mixed solution is reacted under the conditions of 50~140 DEG C, more preferably mixed solution be 80~
Reacted under the conditions of 100 DEG C.When carrying out under normal temperature of the reaction below 80 DEG C or heating condition, when reaction needs longer
Between can just obtain higher yield.
Present invention additionally comprises compound or its pharmaceutically acceptable salt are in antineoplastic is prepared shown in above-mentioned formula (I)
Application.
Present invention additionally comprises prepared with compound or its pharmaceutically acceptable salt shown in above-mentioned formula (I) as active component
Antineoplastic.
Compared with prior art, the invention provides a kind of new with 1- (2- pyridine) -9- benzyl-B-carboline as part
Copper nitrate (II) complex, and its synthetic method and application.Applicant is by investigating its suppression to various tumor cell strains
Make and use, as a result show that the complex has stronger anti tumor activity in vitro, and apparently higher than cis-platinum, with preferably potential
Medical value, is expected to be used for the preparation of various antineoplastics.
Description of the drawings
Fig. 1 is the x-ray crystal structure figure of final product obtained in the embodiment of the present invention 5.
Specific embodiment
With reference to specific embodiment, the present invention is described in further detail, to more fully understand present disclosure, but
The present invention is not limited to following examples.
Embodiment 1:Compound shown in formula (II) is the synthesis of 1- (2- pyridine) -9- benzyl-B-carboline (L)
1) 1.6g (10mmol) tryptamines, 1.1g (10mmol) pyridine-2-formaldehyde and 50ml toluene are added 150ml round bottom to burn
Bottle, adds water knockout drum, condenser pipe group composition water reflux, is heated to reflux 4 hours, and question response terminates rear solvent evaporated, residue
Compound 1 (2.3g, yield 92%) is recrystallized to give with 100ml n-hexane;
2) 2.5g (10mmol) compound 1,2.5g palladium carbon (10%Pd/C) and 100ml paraxylene are added 250ml circle
Bottom flask, is heated to backflow, and is terminated to reaction with thin-layer chromatography tracing detection, and filtrate is simultaneously evaporated by standing suction filtration, and gained is residual
Silica gel column chromatography purifying (V on slagPetroleum ether:VDichloromethane=1:1) compound 2 (2.1g, yield 86%), is obtained;
3) 50ml round-bottomed flask, room temperature are added to 0.24g (10mmol) sodium hydride and 15ml DMF
Stirring 10 minutes, adds 2.5g (10mmol) compound 2 and 1.7g (10mmol) cylite, and uses thin-layer chromatography tracing detection
Terminate to reaction, then reactant liquor is put in 500ml frozen water, extracted three times with 100ml ethyl acetate, merge organic phase, steam
Dry solvent, residue obtained upper silica gel column chromatography purify (VDichloromethane:VMethyl alcohol=100:1) compound 3 (2.9g, yield 87%), is obtained.
Products therefrom is characterized:
(1) proton nmr spectra and carbon spectrum, their spectral data are as follows:
1H NMR(500MHz,CDCl3) δ 8.61 (d, J=4.8Hz, 1H), 8.56 (d, J=5.1Hz, 1H), 8.22 (d, J
=7.8Hz, 1H), 8.07 (d, J=5.1Hz, 1H), 7.63 (td, J=7.6,1.0Hz, 1H), 7.56 (t, J=7.7Hz, 2H),
7.43 (d, J=8.3Hz, 1H), 7.32 (t, J=7.5Hz, 1H), 7.29 7.26 (m, 1H), 7.06 (t, J=7.3Hz, 1H),
7.00 (t, J=7.5Hz, 2H), 6.50 (d, J=7.4Hz, 2H), 5.52 (s, 2H).
13C NMR(126MHz,CDCl3)δ158.40,148.16,143.18,143.10,138.62,137.45,
136.75,134.59,131.63,128.97,128.46,127.13,125.76,125.31,123.09,121.75,121.54,
120.38,114.80,110.58,48.80.
(2) high resolution mass spectrum, ESI-MS m/z:336.0[M+H]+.
Accordingly, it can be determined that above-mentioned product is 1- (2- pyridine) -9- benzyl-B-carboline, its chemical structural formula such as following formula
(II) shown in:
Embodiment 2:The synthesis of ligand L
Repeat embodiment 1, except for the difference that:
Step 2) in, with Mn (Ac)3Replace palladium carbon, replace paraxylene, control Mn (Ac) with glacial acetic acid3Addition be
2 times of the amount of 1 material of compound, reaction are carried out under the conditions of 70 DEG C, and TLC tracing detection terminates to reaction, then will with ammoniacal liquor
The pH of system is adjusted to 7, then is extracted with ethyl acetate three times, merges organic phase, solvent evaporated, residue obtained upper silicagel column (chromatography
Purifying (VPetroleum ether:VDichloromethane=1:1), compound 2 is obtained.
The analysis of proton nmr spectra, carbon-13 nmr spectra and high resolution mass spectrum is carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridine) -9- benzyl-B-carboline.
Embodiment 3:The synthesis of ligand L
Repeat embodiment 2, except for the difference that:
Step 2) in, with Pb (Ac)4Replace Mn (Ac)3, control Pb (Ac)4Addition for 1 material of compound amount 5
Times, reaction is carried out under the conditions of 60 DEG C.
The analysis of proton nmr spectra, carbon-13 nmr spectra and high resolution mass spectrum is carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridine) -9- benzyl-B-carboline.
Embodiment 4:The synthesis of ligand L
Repeat embodiment 1, except for the difference that:
Step 2) in, use chloro- 5, the 6- dicyan 1,4-benzoquinone of 2,3- bis- to replace palladium carbon, replace paraxylene with dichloromethane, 2,
The addition of the chloro- 5,6- dicyan 1,4-benzoquinone of 3- bis- is equal with the amount of the material of compound 1.
The analysis of proton nmr spectra, carbon-13 nmr spectra and high resolution mass spectrum is carried out to the present embodiment products therefrom, is determined
For target product 1- (2- pyridine) -9- benzyl-B-carboline.
Embodiment 5:Title complex [Cu (L) (NO3)2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.1mmol Cu (NO is directly added into3)2·3H2O and 0.1mmol join
Body L, (volume ratio of methyl alcohol and dichloromethane is 3 to add 0.6ml ethanol/methylene mixed solution:1), vacuumizing
Under the conditions of, then openend sealing by fusing fully reacts 20 hours under the conditions of 50 DEG C, obtain green crystal type solid product.
Products therefrom is characterized:
(1) high resolution mass spectrum, ESI-MS m/z:460.06[Cu(L)(NO3)]+.
(2) X-ray single crystal diffraction analysis, as shown in Figure 1.
Therefore can determine that above-mentioned product is the copper nitrate (II) with 1- (2- pyridine) -9- benzyl-B-carboline as part and joins
Compound is title complex [Cu (L) (NO3)2], shown in its structural formula such as following formula (I):
Embodiment 6:Title complex [Cu (L) (NO3)2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.2mmol Cu (NO is directly added into3)2·3H2O and 0.1mmol join
Body L, (volume ratio of ethanol and chloroform is 3 to add 0.6ml ethanol/chloroform mixed solution:1), under conditions of vacuumizing, will
Openend sealing by fusing, then fully reacts 12 hours under the conditions of 80 DEG C, obtains green crystal type solid product.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
Embodiment 7:Title complex [Cu (L) (NO3)2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.3mmol Cu (NO is directly added into3)2·3H2O and 0.1mmol join
Body abbreviation L, adds 0.6ml methanol/ethanol/N,N-dimethylformamide mixed solution (methyl alcohol, ethanol and N, N- dimethyl methyl
The volume ratio of acid amides is 5:1:1), under conditions of vacuumizing, then openend sealing by fusing fully reacts 4 under the conditions of 100 DEG C
Hour, obtain green crystal type solid product.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
Embodiment 8:Title complex [Cu (L) (NO3)2] synthesis
In the heavy wall borosilicate glass tube being open at one end, 0.4mmol Cu (NO is directly added into3)2·3H2O and 0.1mmol join
Body L, (volume ratio of ethanol and acetone is 10 to add 0.6ml ethanol/acetone mixed solution:1), under conditions of vacuumizing,
By openend sealing by fusing, then fully react 4 hours under the conditions of 80 DEG C, obtain green crystal type solid product.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
Embodiment 9:Title complex [Cu (L) (NO3)2] synthesis
Take 6mmol Cu (NO3)2·3H2O and 1mmol ligand L is placed in round-bottomed flask, is added thereto to 80ml ethanol/water
(volume ratio of second alcohol and water is 1 to mixed solution:1), after stirring and dissolving, 60 DEG C are heated to and are reacted 12 hours, reactant decompression is dense
Contracting removes partial solvent, stands, and has green crystal to separate out, isolates solid, washed with ethanol, dries, obtain green crystal.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
Embodiment 10:Title complex [Cu (L) (NO3)2] synthesis
Take 2mmol Cu (NO3)2·3H2O and 1mmol ligand L is placed in round-bottomed flask, is added thereto to 50ml methyl alcohol/the third
(volume ratio of methyl alcohol, acetone and water is 30 to ketone/water mixed solution:1:10), after stirring and dissolving, 50 DEG C of reactions 12 are heated to little
When, reactant reduced pressure concentration removes partial solvent, stands, and has green crystal to separate out, isolates solid, washed with ethanol, dries,
Obtain green crystal.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
Embodiment 11:Title complex [Cu (L) (NO3)2] synthesis
Take 3mmol Cu (NO3)2·3H2O and 1mmol ligand L is placed in round-bottomed flask, is added thereto to 30ml methyl alcohol/chlorine
(volume ratio of methyl alcohol and chloroform is 1 to imitative mixed solution:1), after stirring and dissolving, react 18 hours in 20 DEG C, reactant decompression is dense
Contracting removes partial solvent, stands, and has green crystal to separate out, isolates solid, washed with ethanol, dries, obtain green crystal.
Products therefrom carries out structure determination through high resolution mass spectrum and the analysis of X-ray single crystal diffraction, is defined as target cooperation
Thing [Cu (L) (NO3)2].
In order to absolutely prove purposes of the complex of the present invention in pharmacy, applicant has carried out extracorporeal anti-tumor to which
Activity experiment.
Experimental example 1:Copper nitrate (II) complex with 1- (2- pyridine) -9- benzyl-B-carboline as part is (by reality of the present invention
Apply 5 methods described of example be obtained) and ligand L (by 1 methods described of the embodiment of the present invention be obtained) body is carried out to multiple human tumor strains
Outer inhibitory activity experiment
1st, cell line and cell culture
This experiment is non-from gastric carcinoma cells MGC-803, human hepatoma cell strain Hep G2, human bladder cancer cell T-24, people
Small cell lung cancer cell NCI-H460 and human normal cell line HL-7702 totally 5 kinds of cell lines.
All tumor cell lines are all cultivated containing 10wt% little ox blood, 100U/mL penicillin, 100U/mL streptomysin
In RPMI-1640 nutrient solution, 37 DEG C of 5%CO containing volumetric concentration are put2Cultivate in incubator;Human normal cell line strain is then cultivated and is being contained
In the little ox blood of 10wt%, 100U/mL penicillin, the DMEM nutrient solution of 100U/mL streptomysin.
2nd, the preparation of testing compound
The DMSO liquid storage (concentration is 0.002mol/L) of each testing compound is diluted successively by RMPI1640 culture medium
Become five concentration gradients, respectively 20,10,5,2.5,1.25 μm of ol/L, wherein cosolvent DMSO final concentration≤1%.Survey first
Each testing compound of 20 μm of ol/L of examination is considered as primary dcreening operation result for the inhibiting rate of tumor cell proliferation;Test respectively again different
Proliferation Ability degree of each testing compound to various tumour cells under gradient concentration, in order to the Fitting Calculation half-inhibition concentration,
That is IC50Value.
3rd, cell growth inhibition test (mtt assay)
(1) take the logarithm the tumour cell in growth period, after Trypsin Induced, joined with the nutrient solution containing 10% calf serum
Cell suspension of the concentration for 5000/mL is made, is inoculated in 96 well culture plates with 190 μ L of every hole, makes cell density to be measured extremely
1000~10000/hole (edge hole is filled with aseptic PBS);
(2) 5%CO2, 37 DEG C of incubation 24h, bottom hole is paved with to cell monolayer, add the medicine 10 of finite concentration gradient per hole
μ L, each concentration gradient set 4 multiple holes;
(3) 5%CO2, 37 DEG C are incubated 48 hours, observe under inverted microscope;
(4) the MTT solution (5mg/mL PBS, i.e. 0.5%MTT) of 10 μ L is added per hole, continues culture 4h;
(5) terminate culture, in the hole nutrient solution is carefully sucked, add per hole 150 μ L DMSO that first a ceremonial jade-ladle, used in libation precipitation is fully dissolved, shake
After swinging device mixing, it is 570nm in ELIASA wavelength, reference wavelength is the OD value that 450nm determines each hole;
(6) while arranging zeroing hole (culture medium, MTT, DMSO), (cell, the medicine dissolving of same concentrations are situated between control wells
Matter, nutrient solution, MTT, DMSO).
(7) according to the OD value (OD value) for measuring, judge living cells quantity, OD value is bigger, and cytoactive is stronger.
Calculate the inhibiting rate of compound on tumor cell growth.For cell of the inhibiting rate more than 50% under primary dcreening operation concentration
The inhibiting rate data of five concentration gradients are fitted by SPSS software, obtain compound to different tumours by strain further
Half-inhibition concentration (the IC of strain50Value, unit μm ol/L), compound is for the IC of different cell lines50Value is as shown in table 1.
Table 1:IC of the compound of the present invention to 5 kinds of cell lines50Value (μm ol/L)
From the point of view of anti tumor activity in vitro test result, complex of the present invention has stronger antitumor activity, its
Activity is substantially better than cis-platinum, is expected to develop into antineoplastic.
Claims (10)
1. compound shown in formula (I) or its pharmaceutically acceptable salt are descended:
2. the synthetic method of compound described in claim 1, it is characterised in that:Take compound and nitric acid as shown in following formula (II)
Copper, is dissolved in polar solvent, carries out complexation reaction, that is, obtain target product;Wherein, described polar solvent be selected from methyl alcohol and
One or two and one or two in water, acetone, chloroform, dichloromethane and the DMF in ethanol
Above combination;
3. synthetic method according to claim 2, it is characterised in that:Compound shown in formula (II) and copper nitrate is taken, is dissolved in
In polar solvent, gained mixed liquor is reacted under the conditions of being heated or not heated, and reactant removes partial solvent, is stood, and is separated out, point
Crystal is separated out, obtains final product target product.
4. synthetic method according to claim 3, it is characterised in that:React the reflux temperature model at 50 DEG C to polar solvent
Carry out in enclosing.
5. synthetic method according to claim 2, it is characterised in that:Compound shown in formula (II) and copper nitrate is taken, is dissolved in
In polar solvent, gained mixed liquor is placed in container, is evacuated to vacuum after liquid nitrogen frozen, and sealing by fusing, then in 30~140 DEG C of conditions
Lower reaction, obtains target product.
6. synthetic method according to claim 5, it is characterised in that:Reaction is carried out under the conditions of 50~140 DEG C.
7. the synthetic method according to any one of claim 2~6, it is characterised in that:Compound shown in formula (II)
It is prepared as follows:
With tryptamines and pyridine-2-formaldehyde as raw material, react in the first organic solvent, compound 1 is obtained through dehydrating condensation;So
Afterwards compound 1 is placed in the second organic solvent, adds oxidant cyclization and dehydrogenation obtains compound 2;Again compound 2 is placed in
In the aprotic polar solvent of alkaline matter, add bromination that substitution reaction is carried out, obtain final product;Wherein:
The first described organic solvent be in toluene, methyl alcohol, ethanol, dichloromethane and chloroform one or two with
On combination;
The second described organic solvent be in benzene, toluene, paraxylene, glacial acetic acid and dichloromethane one or two with
On combination;
Described oxidant is palladium carbon, manganese acetate hydrate, lead tetraacetate or the chloro- 5,6- dicyan 1,4-benzoquinone of 2,3- bis-;
Described alkaline matter is inorganic base;
Described aprotic polar solvent is one or two in N,N-dimethylformamide, dimethyl sulfoxide (DMSO) and acetone
Above combination.
8. synthetic method according to claim 7, it is characterised in that:Purifying behaviour is carried out to compound shown in gained formula (II)
Make.
9. the application of compound described in claim 1 or its pharmaceutically acceptable salt in antineoplastic is prepared.
10. the antineoplastic for being prepared with compound described in claim 1 or its pharmaceutically acceptable salt as active component.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610855415.6A CN106478692B (en) | 2016-09-26 | 2016-09-26 | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610855415.6A CN106478692B (en) | 2016-09-26 | 2016-09-26 | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106478692A true CN106478692A (en) | 2017-03-08 |
CN106478692B CN106478692B (en) | 2018-03-20 |
Family
ID=58268949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610855415.6A Active CN106478692B (en) | 2016-09-26 | 2016-09-26 | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106478692B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107118212A (en) * | 2017-05-26 | 2017-09-01 | 广西师范大学 | A kind of beta-carboline compounds and its synthetic method and application |
CN107141285A (en) * | 2017-05-26 | 2017-09-08 | 广西师范大学 | A kind of beta-carboline compounds and its synthetic method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101845060A (en) * | 2010-05-05 | 2010-09-29 | 中山大学 | Beta-carboline ruthenium compound as well as preparation method and application thereof |
EP2508570A2 (en) * | 2009-12-02 | 2012-10-10 | SFC Co., Ltd. | Organic metal dye, and photoelectric element and dye-sensitized solar cell using the organic metal dye |
CN103254239A (en) * | 2013-03-20 | 2013-08-21 | 中山大学 | aryl ruthenium-beta-carboline complex and its preparation method and application |
-
2016
- 2016-09-26 CN CN201610855415.6A patent/CN106478692B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2508570A2 (en) * | 2009-12-02 | 2012-10-10 | SFC Co., Ltd. | Organic metal dye, and photoelectric element and dye-sensitized solar cell using the organic metal dye |
CN101845060A (en) * | 2010-05-05 | 2010-09-29 | 中山大学 | Beta-carboline ruthenium compound as well as preparation method and application thereof |
CN103254239A (en) * | 2013-03-20 | 2013-08-21 | 中山大学 | aryl ruthenium-beta-carboline complex and its preparation method and application |
Non-Patent Citations (4)
Title |
---|
CAIPING TAN等: "Nuclear Permeable Ruthenium(II)β-Carboline Complexes Induce Autophagy To Antagonize Mitochondrial-Mediated Apoptosis", 《J. MED. CHEM.》 * |
KE-BIN HUANG等: "Copper(II/I) complexes of 5-pyridin-2-yl-[1,3]dioxolo[4,5-g]isoquinoline: Synthesis, crystal structure, antitumor activity and DNA interaction", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
LIANG HE等: "Cyclometalated iridium(III)–β-carboline complexes as potent autophagy-inducing agents", 《CHEM. COMMUN.》 * |
LIANG HE等: "Ruthenium–Arene–β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies", 《CHEM. EUR. J.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107118212A (en) * | 2017-05-26 | 2017-09-01 | 广西师范大学 | A kind of beta-carboline compounds and its synthetic method and application |
CN107141285A (en) * | 2017-05-26 | 2017-09-08 | 广西师范大学 | A kind of beta-carboline compounds and its synthetic method and application |
Also Published As
Publication number | Publication date |
---|---|
CN106478692B (en) | 2018-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106632424B (en) | Using 1- (2- pyridines) -9- benzyls-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
CN106478692B (en) | Using 1 (2 pyridine) 9 benzyl β carbolines as the copper-nitrate complex and its synthetic method of part and application | |
CN106632421B (en) | The copper-nitrate complex and its synthetic method of 1- (2- pyridines) -9- (4- methylbenzyls)-B-carboline and application | |
CN106632420A (en) | Copper chloride complex by taking 1-(2-pyridine)-9-butyl-beta-carboline as ligand as well as synthetic method and application of complex | |
CN106478687B (en) | Using 1- (2- pyridines) -9- ethyl-beta-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
CN106478690A (en) | The chlorination copper complex of 1 (2 pyridine) 9 (4 phenyl butyl) β carboline and its synthetic method and application | |
CN106478686B (en) | Using 1 (2 pyridine) 9 ethyl β carbolines as the copper-nitrate complex and its synthetic method of part and application | |
CN106432287B (en) | The copper-nitrate complex of 1 (2 pyridine) 9 (2 ethoxyethyl group) β carbolines and synthetic method and application | |
CN106478677B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (2 Phenoxyethyl) β carbolines and synthetic method and application | |
CN106478678B (en) | The copper-nitrate complex of 1 (2 pyridine) 9 (methyl of naphthalene 2) β carbolines and its synthetic method and application | |
CN106478676B (en) | The copper-nitrate complex of 1 (2 pyridine) 9 (2 Phenoxyethyl) β carbolines and synthetic method and application | |
CN106478679B (en) | The copper-nitrate complex of 1 (2 pyridine) 9 Cvclopropvlmethvl β carbolines and its synthetic method and application | |
CN106478688B (en) | Using 1- (2- pyridines) -9- methyl-ss-carbolines as the chlorination copper complex and its synthetic method of ligand and application | |
CN106632414B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (2 ethoxyethyl group) β carbolines and synthetic method and application | |
CN106432289B (en) | Using 1 (2 pyridine) 9 amyl group β carbolines as the chlorination copper complex and its synthetic method of part and application | |
CN106432288B (en) | The copper-nitrate complex of 1 (2 pyridine) 9 (2 Benzyloxyethyl) β carbolines and synthetic method and application | |
CN106632415B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (methyl of naphthalene 2) β carbolines and its synthetic method and application | |
CN106478675B (en) | The chlorination copper complex of 1 (2 pyridine) 9 (2 Benzyloxyethyl) β carbolines and synthetic method and application | |
CN106478689B (en) | The chlorination copper complex of 1- (2- pyridines) -9- (4- methyl-benzyls)-B-carboline and its synthetic method and application | |
CN106632416B (en) | Using 1- (2- pyridines) -9- isopentyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
CN106478684B (en) | Using 1- (2- pyridines) -9- heptyl-B-carboline as the chlorination copper complex and its synthetic method of ligand and application | |
CN106478683A (en) | Chlorination copper complex and its synthetic method and application with 1 (2 pyridine) 9 isobutyl group β carboline as part | |
CN106478681A (en) | The copper-nitrate complex of 1 (2 pyridine) 9 (4 luorobenzyl) β carboline and its synthetic method and application | |
CN106478680A (en) | The chlorination copper complex of 1 (2 pyridine) 9 Cvclopropvlmethvl β carboline and its synthetic method and application | |
CN106478682A (en) | The chlorination copper complex of 1 (2 pyridine) 9 (4 luorobenzyl) β carboline and its synthetic method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |